Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03210974
Other study ID # ÁLAMO IV
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 3, 2016
Est. completion date March 1, 2021

Study information

Verified date March 2023
Source Spanish Breast Cancer Research Group
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is a non-interventional (NIS), multicenter, retrospective cohort study, which will obtain data from patients diagnosed with invasive breast cancer between 2002 and 2005 in the medical oncology departments of hospitals that are members of GEICAM (using information obtained from patient medical histories).


Description:

There is no specific treatment regimen for this study. This is an observational retrospective study in which the clinical decisions concerning the optimal strategy in the treatment of the disease for each patient have been taken independently and prior to the physician's decision to include patient data in this registry, in keeping with the drug information, local treatment guidelines and/or standard clinical practice. The study target population are all patients (men and women) who have been newly diagnosed with invasive breast cancer between January 1, 2002 and December 31, 2005 and treated in the medical oncology departments of participating sites, ensuring an approximate follow-up of 10 years.


Recruitment information / eligibility

Status Completed
Enrollment 13135
Est. completion date March 1, 2021
Est. primary completion date March 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients whose first primary breast invasive tumor diagnosis occurred between January 1, 2002 and December 31, 2005 and who have received treatment in the medical oncology departments of participating sites. - Patients who were diagnosed at the participating site; otherwise the site where the initial diagnosis was made should be contacted with in order to confirm that the patient has not already been enrolled in the study or pending inclusion. The objective is to avoid duplicate records for displaced patients. Exclusion Criteria: - Patients with a single diagnosis of in situ carcinoma (without infiltrating component).

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Spain Centro Oncológico de Galicia A Coruña
Spain Complejo Hospitalario Universitario A Coruña A Coruña
Spain Complejo Hospitalario de Albacete Albacete
Spain Hospital Universitario Fundación Alrcorcón Alcorcón Madrid
Spain Hospital Virgen de los Lirios Alcoy Valencia
Spain Hospital General Universitario de Alicante Alicante
Spain Hospital Nuestra Señora de Sonsoles Ávila
Spain Hospital Universitario Germans Trias i Pujol Badalona Barcelona
Spain Hospital Clinic i Provincial Barcelona
Spain Hospital del Mar Barcelona
Spain Hospital Universitario de Basurto Bilbao Vizcaya
Spain Hospital Universitario Puerta del Mar Cadiz
Spain Hospital General Virgen de la Luz Cuenca
Spain Hospital Universitario de Donostia Donostia-San Sebastián Gupúzcoa
Spain Onkologikoa Donostia-San Sebastián Guipuzcoa
Spain Hospital General Universitario de Elche Elche Alicante
Spain Hospital General Universitario de Elda - Virgen de la Salud Elda Alicante
Spain Hospital Universitario de Fuenlabrada Fuenlabrada Madrid
Spain Hospital Josep Trueta Girona
Spain Hospital General de Granollers Granollers Barcelona
Spain Hospital Universitario Canarias La Laguna Santa Cruz De Tenerife
Spain Hospital Universitario de Gran Canaria Doctor Negrín Las Palmas de Gran Canaria Las Palmas
Spain Hospital Universitario Lucus Augusti Lugo
Spain Hospital General Universitario Gregorio Marañón Madrid
Spain Hospital Universitario La Prinesa Madrid
Spain Hospital Universitario Puerta de Hierro de Majadahonda Majadahonda Madrid
Spain Hospital de Mataró-Consorci Sanitari del Maresme Mataró Barcelona
Spain Hospital Clínico Universitario Virgen de la Arrixaca Murcia
Spain Complejo Hospitalario Universitario de Ourense Ourense
Spain Hospital Universitario Central de Asturias Oviedo Asturias
Spain Clínica Universidad de Navarra Pamplona Navarra
Spain Corporació Sanitaria Parc Taulí Sabadell Barcelona
Spain Consorci Sanitari de Terrassa Terrassa Barcelona
Spain Hospital Universitario Virgen de la Salud Toledo
Spain Hospital Clínico Universitario de Valencia Valencia
Spain Hospital General Universitario de Valencia Valencia
Spain Hospital Universitari i Politécnic La Fe Valencia
Spain Hospital Universitario Dr. Peset Valencia
Spain Instituto Valenciano de Oncología Valencia
Spain Hospital Clínico Universitario de Zaragoza Lozano Blesa Zaragoza
Spain Hospital Universitario Miguel Servet Zaragoza

Sponsors (2)

Lead Sponsor Collaborator
Spanish Breast Cancer Research Group Instituto de Salud Carlos III

Country where clinical trial is conducted

Spain, 

References & Publications (1)

Lopez-Tarruella S, Escudero MJ, Pollan M, Martin M, Jara C, Bermejo B, Guerrero-Zotano A, Garcia-Saenz J, Santaballa A, Alba E, Andres R, Martinez P, Calvo L, Fernandez A, Batista N, Llombart-Cussac A, Anton A, Lahuerta A, de la Haba J, Lopez-Vega JM, Car — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Study demographic Number of participants with the demographic characteristics: Age, sex, race of new cases of breast cancer diagnosed from 2002 to 2005 in Spanish hospitals. 30 months
Primary Study clinical and anatomic-pathological In the 12.000 patients included to study the clinical and anatomic-pathological characteristics: primary tumor, regional nodes, metastasis status (TNM), date of initial diagnosis of Breast Cancer (BC), biomarkers of new cases of breast cancer diagnosed from 2002 to 2005 in Spanish hospitals 30 months
Secondary Evolution of Breast Cancer in terms of frequency In the 12.000 patients included to describe the evolution of breast cancer patients in terms of frequency (time). 30 months
Secondary Evolution of Breast Cancer in terms of type In the 12.000 patients included to describe the evolution of breast cancer patients in terms of type of relapse. 30 months
Secondary Evolution of Breast Cancer in terms of location of relapse In the 12.000 patients included to describe the evolution of breast cancer patients in terms of location of relapse. 30 months
Secondary Family history of Breast Cancer Number of patients with a family history of breast cancer. 30 months
Secondary Characteristics of family history of Breast Cancer Characteristics clinical-pathological of patients with a family history of breast cancer. 30 months
Secondary Differences in Breast Cancer between sex Differences clinical-pathological between men and women with breast cancer 30 months
Secondary Quantify the influence of type of surgery conducted on primary tumor In the 12.000 patients included to quantify the influence of type of surgery conducted on primary tumor 30 months
Secondary Number of patients with metastatic disease as first diagnosis In the 12.000 patients included to quantify the influence of timepoint of primary tumor surgery in patients with metastatic disease as first diagnosis 30 months
Secondary Quantify the prevalence of breast cancer related to pregnancy In the 12.000 patients included to quantify the prevalence of breast cancer related to pregnancy 30 months